ALB and neoplasm: The maximal tumor size, tumor type, ECOG performance status, Child–Pugh score, serum total bilirubin, albumin, and AFP levels did not differ significantly between the two groups, whereas the proportion of patients with a tumor number ≥ 4 was higher in the TACE-alone group than in the TACE plus sorafenib group (37% vs. 20%; p = 0.012), and the proportion of patients with main PV or IVC invasion was higher in the TACE plus sorafenib group than in the TACE-alone group (22% vs. 9%; p = 0.016).